Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

Share:
Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plunged more than 15 percent Monday morning and hit a new 52-week low of $109.80 after the company's board of directors announced CEO David Hallal will leave the company amid an ongoing audit and finance committee investigation.

The company's chief financial officer Vikas Sinha will also leave the company to pursue opportunities.

Management Changes

A CNBC report suggested that the board lost confidence in both Hallal and Sinha although it is unclear why.

In a brief research report on Monday Heather Behanna of Wedbush noted that Alexion's audit and finance Committee announcement that it has not yet identified any facts that would require an update to its prior financial results could be seen as a "positive" — especially since eculizumab generates more than 90 percent of the company's top-line revenues.

Accordingly, the analyst believes that there will be no revenue adjustment, which in turn has no affect on her prior stock rating of Neutral and $135 price target.

Remaining Risks

Behanna reiterated that prior risks on the stocks remain in place, including:

    1. Clinical risk that eculizumab will fail to demonstrate efficacy in other diseases driven by upstream complement dysfunction.
    2. The possibility that Alexion's pipeline candidates fails to move forward in development.
    3. Regulatory risk that the company may not be able to obtain approval for its compounds.
    4. Commercial risk that the company may not be able to demonstrate organic top-line growth of its commercialized therapies.
    5. Competitive risks include other companies who can come to the market and take share.
    6. There is also the risk that the company may need to reduce its reported eculizumab revenues pending the outcome of the investigation.

Alexion shares were down 15.36 percent at $111.70 at last check.

Latest Ratings for ALXN

DateFirmActionFromTo
May 2019MaintainsBuy
May 2019AssumesNeutral
May 2019Initiates Coverage OnOutperform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings News Health Care Reiteration Management Analyst Ratings Best of Benzinga

 

Related Articles (ALXN)

View Comments and Join the Discussion!

Worst Performing Industries For December 12, 2016

EUR/USD Gains Erode Ahead of Data